Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

NCT01211639 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01211639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01211639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
Lead sponsor
Biogen
Phase
Observational
Overall status
Terminated
Start date
October 31, 2010
Completion date
August 31, 2014
Enrollment
24 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

progressive multifocal leukoencephalopathy